welcome
Investor's Business Daily

Investor's Business Daily

Business

Business & Economics

Shares of Vertex Pharmaceuticals slip on first-quarter setbacks

Investor's Business Daily
Summary
Nutrition label

81% Informative

Vertex Pharmaceuticals tumbled more than 12% to 436.68 after the stock market opened Tuesday .

The company missed first-quarter sales of $2.77 billion , lagging the Street's call for $4.25 billion .

Revenue from Vertex 's new cystic fibrosis drug, Alyftrek , came in light at $53.9 million .

The news sent Crispr stock down 3% to 36.48 .

VR Score

86

Informative language

92

Neutral language

67

Article tone

formal

Language

English

Language complexity

40

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links